These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
195 related items for PubMed ID: 3136953
1. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D. Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953 [Abstract] [Full Text] [Related]
2. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I, Collen D. Circulation; 1986 Feb; 73(2):347-52. PubMed ID: 3080262 [Abstract] [Full Text] [Related]
3. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Circulation; 1989 May; 79(5):980-9. PubMed ID: 2496939 [Abstract] [Full Text] [Related]
4. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171 [Abstract] [Full Text] [Related]
5. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. Kalbfleisch J, Thadani U, LittleJohn JK, Brown G, Magorien R, Kutcher M, Taylor G, Maddox WT, Campbell WB, Perry J. Am J Cardiol; 1992 May 01; 69(14):1120-7. PubMed ID: 1575179 [Abstract] [Full Text] [Related]
7. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Verstraete M, Arnold AE, Brower RW, Collen D, de Bono DP, De Zwaan C, Erbel R, Hillis WS, Lennane RJ, Lubsen J. Am J Cardiol; 1987 Aug 01; 60(4):231-7. PubMed ID: 3113222 [Abstract] [Full Text] [Related]
12. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, Py A, Pilcher GS, Fink CA, Burton JR. J Am Coll Cardiol; 1994 Nov 15; 24(6):1439-44. PubMed ID: 7930273 [Abstract] [Full Text] [Related]
13. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL. J Am Coll Cardiol; 1994 Apr 15; 23(5):993-1003. PubMed ID: 8144799 [Abstract] [Full Text] [Related]
14. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. GUSTO Angiographic Investigators. N Engl J Med; 1993 Nov 25; 329(22):1615-22. PubMed ID: 8232430 [Abstract] [Full Text] [Related]